Suppl. Table 13.
The main PK parameters of astragaloside III in rat plasma after oral administration of different formulations. (Mean ± SD, n = 6)
| Parameter | Group | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| formulation 1 | formulation 2 | formulation 3 | formulation 4 | formulation 5 | formulation 6 | formulation 7 | formulation 8 | formulation 9 | |
| T1/2(h) | 13.25 ± 1.49 | 15.77 ± 2.06 | 13.91 ± 2.45 | 15.47 ± 1.48 | 15.77 ± 1.88 | 13.17 ± 1.08 | 11.72 ± 1.44 | 13.48 ± 1.29 | 13.82 ± 1.78 |
| Tmax(h) | 0.79 ± 0.06 | 0.85 ± 0.05 | 0.64 ± 0.03 | 0.55 ± 0.07 | 0.75 ± 0.18 | 0.57 ± 0.04 | 0.59 ± 0.05 | 0.78 ± 0.07 | 0.54 ± 0.02 |
| Cmax(μg/L) | 71.63 ± 3.54 | 49.97 ± 10.25 | 110.29 ± 21.22 | 20.95 ± 5.64 | 48.83 ± 5.97 | 53.1 ± 12.64 | 36.32 ± 9.81 | 49.37 ± 10.64 | 123.21 ± 18.61 |
| AUC(0-t) (μg/L*h) | 298.97 ± 29.64 | 257.15 ± 35.26 | 394.06 ± 37.87 | 193.91 ± 39.44 | 260.61 ± 28.89 | 236.89 ± 25.47 | 326.461 ± 41.52 | 314.77 ± 174.16 | 388.47 ± 169.63 |
| MRT(0-t) (h) | 9.11 ± 1.09 | 8.26 ± 1.47 | 7.55 ± 0.87 | 9.27 ± 0.44 | 8.15 ± 0.68 | 7.81 ± 0.97 | 7.99 ± 1.08 | 8.27 ± 1.44 | 7.29 ± 1.99 |